Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to begin a pivotal clinical study of the Triadyme®‑C cervical artificial disc. This achievement marks a critical milestone in the company’s mission to bring the...

Dymicron®, a pioneering medical technology company renowned for its revolutionary cervical spine disc replacement solution, has announced the appointment of Dominik Wilke as its new Senior Manager, Business Development and Marketing. With over a decade of experience in the spinal device industry, Dominik brings a wealth of expertise and a passion for innovation to his new...